The DOI matches its Crossref record; 273 of the 279 references it cites were found in a registry or an index.
Delivering affordable cancer care in high-income countries
Abstract
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The indirect economic costs associated with premature death and lost productivity from the growing cancer burden have been estimated at US$1.16 trillion a year,3 or approaching 2% of global GDP.103”
Citations
Cites
Items 201–273 of 273
Imaging in Radiation Oncology: A Perspective
Dawson, L. A., & Ménard, C. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-s106 · Cited by 42
Making cost assessments based on RCTs more useful to decision-makers
Baltussen, R. M. P. M., Ament, A. J. H. A., & Leidl, R. (1996) · Health Policy · doi:10.1016/s0168-8510(96)90023-8 · Cited by 42
Neal, J. W., Heist, R. S., Fidias, P. M., Temel, J. S., Huberman, M. S., Marcoux, J. P., Muzikansky, A., Lynch, T. J., & Sequist, L. V. D. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f0bee0 · Cited by 41
The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center
Klamerus, J. F. A., Bruinooge, S. S., Ye, X., Klamerus, M. L., Damron, D. J., Lansey, D. G., Lowery, J. C., Diaz, L. A., Ford, J. G., Kanarek, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1451 · Cited by 41
Value and Cancer Care: Toward an Equitable Future
Schnipper, L. E., Meropol, N. J., & Brock, D. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1643 · Cited by 39
Self-citationTurnaround: Time to Take a Look
Sandler, M. P. (2001) · Journal of Nuclear Medicine · Cited by 39
Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms
Golec, J. H., & Vernon, J. A. (2010) · PharmacoEconomics · doi:10.2165/11535580-000000000-00000 · Cited by 38
10 years of NICE: still growing and still controversial
Littlejohns, P., Garner, S. E., Doyle, N., Macbeth, F. R., Barnett, D. B., & Longson, C. M. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70077-4 · Cited by 38
LoRusso, P. M., Anderson, A. B., Boerner, S. A., & Averbuch, S. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1279 · Cited by 37
Bystander effects and their implications for clinical radiotherapy
Munro, A. J. (2009) · Journal of Radiological Protection · doi:10.1088/0952-4746/29/2a/s09 · Cited by 36
Criteria for deciding cost-effectiveness for expensive new anti-cancer agents
Sarin, R. (2008) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.39685 · Cited by 35
Introduction: The prevention agenda
O’Callaghan, T. (2011) · Nature · doi:10.1038/471s2a · Cited by 34
Foster, J. A., Abdolrasulnia, M., Doroodchi, H., McClure, J. S., & Casebeer, L. L. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0049 · Cited by 33
Need for global action for cancer control
Boyle, P., Anderson, B. O., Andersson, L. C., Ariyaratne, Y., Auleley, G.-R., Barbacid, M., Bartelink, H. G. M. M., Baselga, J. M., Behbehani, K., Belardelli, F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn426 · Cited by 33
Self-citationAnti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET
Honer, M., Ebenhan, T., ALLEGRINI, P. R., Ametamey, S. M., Becquet, M., Cannet, C., Lane, H. A., O’Reilly, T., Schubiger, P. A., Sticker-Jantscheff, M., et al. (2010) · Translational Oncology · doi:10.1593/tlo.10127 · Cited by 33
Emerging Lessons From The Drug Effectiveness Review Project
Neumann, P. J. (2006) · Health Affairs · doi:10.1377/hlthaff.25.w262 · Cited by 32
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100
Younis, T., Rayson, D., Sellon, M., & Skedgel, C. D. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9770-x · Cited by 30
Fraser, J., Steele, N. L., Zaman, A. A., & Yule, A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.001 · Cited by 29
Trends In Underinsurance And The Affordability Of Employer Coverage, 2004–2007
Gabel, J. R., McDevitt, R. D., Lore, R., Pickreign, J. D., Whitmore, H., & Ding, T. (2009) · Health Affairs · doi:10.1377/hlthaff.28.4.w595 · Cited by 29
A review of economic evaluations of genetic testing services and interventions (2004–2009)
Djalalov, S., Musa, Z., Mendelson, M., Siminovitch, K. A., & Hoch, J. S. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182003294 · Cited by 29
Reforming Health Care Reform in the 112th Congress
Antos, J. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1012299 · Cited by 29
Gellad, W. F., Schneeweiß, S., Brawarsky, P., Lipsitz, S. R., & Haas, J. S. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0689-7 · Cited by 28
Proton radiation in the management of localized cancer
Paganetti, H., & Kooy, H. M. (2010) · Expert Review of Medical Devices · doi:10.1586/erd.10.2 · Cited by 26
PET/MRI: a different spin from under the rim
Hicks, R. J., & Lau, E. W. F. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0966-z · Cited by 25
Self-citationEORTC Cutaneous Lymphoma Task Force
Knobler, R., Burg, G., Whittaker, S. J., & Baila, L. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00466-x · Cited by 25
Moeremans, K., & Annemans, L. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00699.x · Cited by 25
Reed, S., Shea, A. M., & Schulman, K. A. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0246-9 · Cited by 24
Self-citationWhy do we love medicines so much?
Sullivan, R. J., Behncke, I., & Purushotham, A. D. (2010) · EMBO Reports · doi:10.1038/embor.2010.108 · Cited by 23
Self-citationBreast cancer in elderly women. Optimizing the treatment
Gennari, R., & Audisio, R. A. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9723-4 · Cited by 23
Solomon, B., McArthur, G. A., Cullinane, C. M., Zalcberg, J. R., & Hicks, R. J. (2003) · BioDrugs · doi:10.2165/00063030-200317050-00004 · Cited by 22
Self-citationImplications of comparative effectiveness research for radiation oncology
Bekelman, J. E., Shah, A., & Hahn, S. M. (2011) · Practical Radiation Oncology · doi:10.1016/j.prro.2011.02.001 · Cited by 21
Where's the Value in Health Care?
Hay, J. W. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00093.x · Cited by 21
Advances in Cancer Therapeutics and Patient Access to New Drugs
Dranitsaris, G., Truter, I., Lubbe, M. S., Amir, E., & Evans, W. K. (2010) · PharmacoEconomics · doi:10.2165/11584210-000000000-00000 · Cited by 21
Self-citationRidder, M. D., Verovski, V. N., Darville, M. I., den Berge, D. L. V., Monsaert, C., Eizirik, D. L., & Storme, G. A. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.065 · Cited by 20
Self-citationA policy approach to the development of molecular diagnostic tests
Schulman, K. A., & Tunis, S. (2010) · Nature Biotechnology · doi:10.1038/nbt1110-1157 · Cited by 20
Self-citationTappenden, P., Chilcott, J. B., Brennan, A., & Pilgrim, H. (2009) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309990407 · Cited by 20
Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009
Savage, P. M. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210389218 · Cited by 19
Steinberg, M. L., & Konski, A. A. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181af5b5c · Cited by 18
Self-citationWhat is the value of oncology medicines?
Cohen, J., & Looney, W. (2010) · Nature Biotechnology · doi:10.1038/nbt1110-1160 · Cited by 16
Uncertainty aversion: a discussion of critical issues in health economics
Wakker, P. P. (2000) · Health Economics · doi:10.1002/(sici)1099-1050(200004)9:3 · Cited by 16
Marino, P., Siani, C., Roche, H. H., Protière, C., Fumoleau, P., Spielmann, M., Martin, A., Viens, P., & Corroller, A. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp561 · Cited by 16
Wallner, P. E., & Konski, A. A. (2008) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2008.06.008 · Cited by 15
Concerns About Provenge Simmer as CMS Ponders Coverage
Goozner, M. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr041 · Cited by 14
Goodman, R. L. (2010) · Academic Medicine · doi:10.1097/acm.0b013e3181dbb55b · Cited by 13
How can we tell if PET imaging for cancer is cost effective?
MacManus, M. P., & Hicks, R. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70164-9 · Cited by 12
Self-citationHealth Technology Assessment of PET in oncology: re Eur J Nucl Med Mol Imaging 2003; 30:637?641
Kristensen, F. B., Adams, E., Briones, E., Coburn, D., Facey, K. M., Hansen, N., Hoeksema, J., & M�rland, B. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1391-y · Cited by 12
The risk of exaggerated risk aversion—a life and death struggle for molecular imaging
Långström, B., Grahnén, A., Honoré, P. H., Borlak, J. T., Bergström, M., Nielsen, B., Vanderheyden, J., Yasuyoshi, W., Josephsson, R., Høilund‐Carlsen, P. F., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1190-1 · Cited by 12
Self-citationDespite steep costs, payments for new cancer drugs make economic sense
Lichtenberg, F. R. (2011) · Nature Medicine · doi:10.1038/nm0311-244 · Cited by 11
The state of research into children with cancer across Europe: new policies for a new decade
Pritchard‐Jones, K., Lewison, G., Camporesi, S., Vassal, G., Ladenstein, R., Benoit, Y., Predojevic, J. S., Sterba, J., Stary, J., Eckschlager, T., et al. (2011) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 11
Self-citationWald, N., & OPPENHEIMER, P. M. (2011) · Journal of Medical Screening · doi:10.1258/jms.2010.010136 · Cited by 10
Oncologists Judge Themselves the Best Judges of Cancer Treatments
Thakkar, S. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.16.1188 · Cited by 10
Meropol, N. J., Lyman, G. H., Chien, R., & Hornberger, J. C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.4_suppl.491 · Cited by 10
Self-citationLate-stage cancer detection in the USA is costing lives
Lancet, T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62195-2 · Cited by 10
Oncologists protest about NICE's decision on cancer drugs
Dyer, O. (2002) · BMJ · doi:10.1136/bmj.324.7351.1413 · Cited by 7
Adams, E., Almazán, C., Mørland, B., Bradbury, I., King, R., & Rheinberger, P. (2006) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462306050951 · Cited by 7
Are Health Economics Making Us Sick?
Hicks, R. J., & Borland, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079772 · Cited by 7
Self-citationNuclear medicine and thyroid cancer
Jana, S., ABDEL-DAYEM, H. M., & Young, I. S. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050490 · Cited by 6
Health technology assessment and cancer imaging: who should be setting the agenda?
Hicks, R. J. (2004) · Cancer Imaging · doi:10.1102/1470-7330.2004.0009 · Cited by 5
Self-citationCosts of health care: a lopsided debate
Ell, P. J., & Deszy, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050408 · Cited by 4
Self-citationAlkhayyat, S. S., Dent, S. F., Verreault, J., Robinson, A. G., Germond, C. J., & Vandenberg, T. A. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-2087 · Cited by 4
Inferring the value of medical research to the UK
McGuire, A. J., & Raikou, M. (2007) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 3
Elkharrat, D., Chevret, S., A, L. C., & Benhamou, F. (1999) · Value in Health · doi:10.1016/s1098-3015(11)70974-3 · Cited by 3
The overthrow of the (evidence) hierarchy
Steinberg, M. L. (2011) · Practical Radiation Oncology · doi:10.1016/j.prro.2011.02.002 · Cited by 3
Self-citationGrowing Calls in United States, Europe to Improve Regulation of Genetic Testing
Kuehn, B. M. (2009) · JAMA · doi:10.1001/jama.2009.1341 · Cited by 3
We have met the enemy and he is us!
DeVita, V. T. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.89 · Cited by 2
Hershman, D., Neugut, A. I., Subar, M., Wilde, E., Stratton, S., Brouse, C., Hillyer, G. C., & Grann, V. R. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s6-4 · Cited by 2
NICE system…shame about the side-effects
Mcvie, G. J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01043-x · Cited by 1
Geographic Analysis: Need For Better Data
Ricketts, T. C., & Holmes, M. (2009) · Health Affairs · doi:10.1377/hlthaff.28.2.595-a · Cited by 1
Butowski, N. A., Lamborn, K. R., Polley, M. C., Clarke, J. L., Nicole, A., Page, M., Nicol, S. J., Thornton, D., Chang, S., & Prados, M. D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2050 · Cited by 1
Shaughnessy, J. D., Qu, P., Haessler, J., Crowley, J. J., & Barlogie, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8538 · Cited by 1
Sabatino, S., Thompson, T., Richardson, L., & Miller, J. W. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-pd08-01 · Cited by 1
Rodriguez, J., Bandrés, E., Hernandez, A., Zárate, R., Boni, V., Ponz‐Sarvisé, M., Bitarte, N., & García‐Foncillas, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13579 · Cited by 1
Bastian, G., Chibaudel, B., Maindrault‐Gœbel, F., Garcia-Hejl, C., Bonnetain, F., Rebischung, C., Hebbar, M., Yataghene, Y., & de Gramont, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15024 · Cited by 1
Research works printed but not linked: 2
- Jönsson, 2007, The burden and cost of cancer, Ann Oncol, 18, 8
- Stark, 2009, The burden of cancer in Europe and the availability of cancer drugs, EJHP Practice, 15, 20
Cited by
Sorted by citations
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614
The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
Self-citationEconomic burden of cancer across the European Union: a population-based cost analysis
Luengo-Fernández, R., Leal, J., Gray, A. M., & Sullivan, R. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70442-x · Cited by 1,055
Self-citationDelivering High-Quality Cancer Care: Charting a New Course for a System in Crisis
Levit, L. A., Balogh, E. P., Nass, S. J., & Ganz, P. A. (2014) · Cited by 956
Metadata
- Authors
- Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J. G., Purushotham, A. D., Naredi, P., Eggermont, A., Brennan, M. F., Steinberg, M. L., De Ridder, M., McCloskey, S. A., Verellen, D., Roberts, T., Storme, G., Hicks, R. J., Ell, P. J., Hirsch, B. R., Carbone, D. P., Schulman, K. A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N. G., Meltzer, D., Kerr, D., & Aapro, M.
- Affiliations
- Guy's Hospital (GB)
- Duke Medical Center (US)
- The University of Melbourne (AU)
- University Hospitals Seidman Cancer Center (US)
- University of Toronto (CA)
- Pitié-Salpêtrière Hospital (FR)
- International Prevention Research Institute (FR)
- National Cancer Institute (US)
- Austin Hospital (AU)
- Northumbria Healthcare NHS Foundation Trust (GB)
- King's College London (GB)
- European Institute of Oncology (IT)
- Umeå University (SE)
- Institut Gustave Roussy (FR)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- Vrije Universiteit Brussel (BE)
- Peter MacCallum Cancer Centre (AU)
- University College London (GB)
- Duke University (US)
- Vanderbilt University Medical Center (US)
- Association of the British Pharmaceutical Industry (GB)
- University of London (GB)
- Susan G. Komen Breast Cancer Foundation (US)
- University of Chicago (US)
- University of Oxford (GB)
- Clinique de Genolier (CH)
- Corresponding author
- Sullivan, Richard
- ORCID
- Sullivan, Richard
- Peppercorn, Jeffrey
- Sikora, Karol
- Zalcberg, John
- Meropol, Neal J
- Amir, Eitan
- Boyle, Peter
- Autier, Philippe
- Tannock, Ian F
- Fojo, Tito
- Siderov, Jim
- Williamson, Steve
- Camporesi, Silvia
- Purushotham, Arnie D
- Naredi, Peter
- Eggermont, Alexander
- Brennan, Murray F
- Steinberg, Michael L
- McCloskey, Susan A
- Verellen, Dirk
- Storme, Guy
- Hicks, Rodney J
- Schulman, Kevin A
- Taylor, David
- Geissler, Jan
- Meltzer, David
- Kerr, David
- Aapro, Matti
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 12
- Issue
- 10
- Pages
- 933-980
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2111285159
- Cited by
- 718
- References
- 279
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 34 · 2023: 16 · 2022: 33 · 2021: 43 · 2020: 40 · 2019: 32 · 2018: 60 · 2017: 45 · 2016: 56 · 2015: 67 · 2014: 75 · 2013: 81 · 2012: 76
- FWCI
- 199.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Conquer Cancer Foundation
- King's College Hospital NHS Foundation Trust
- National Institute for Health and Care Research
- Department of Health and Social Care
- King's College London
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
- Keywords
- cancer costs, high-income countries, value-based pricing, access to cancer treatment, health equity, regulatory regimes, health policy, overuse of health care
- MeSH terms
- Australia, Cost-Benefit Analysis, Europe, Health Expenditures, Health Policy, Health Services Accessibility, Health Services Misuse, Health Services Research, Humans, Insurance, Health, Neoplasms, Socioeconomic Factors, United States, Cost Savings, Health Care Costs, Health Care Reform, Models, Economic, Delivery of Health Care, Integrated, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
